Thymosin Alpha-1: Past Clinical Experience and Future Therapeutic Promise

Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — the most clinically advanced immune peptide drug.

Tuthill, Cynthia et al.·Annals of the New York Academy of Sciences·2010·
RPEP-017062010RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — the most clinically advanced immune peptide drug.

Key Numbers

How They Did This

research study.

Why This Research Matters

Relevant for peptide research.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.

Trust & Context

Key Stat:
Key finding Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — th
Evidence Grade:
emerging evidence.
Study Age:
Published in 2010.
Original Title:
Thymosin alpha 1: past clinical experience and future promise.
Published In:
Annals of the New York Academy of Sciences, 1194, 130-5 (2010)
Database ID:
RPEP-01706

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

Thymosin Alpha-1: Past Clinical Experience and Future Therapeutic Promise

What was found?

Updated review of thymosin alpha-1 clinical experience spanning hepatitis B/C, cancer immunotherapy, vaccine adjuvancy, and emerging applications — the most clinically advanced immune peptide drug.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-01706·https://rethinkpeptides.com/research/RPEP-01706

APA

Tuthill, Cynthia; Rios, Israel; McBeath, Randy. (2010). Thymosin alpha 1: past clinical experience and future promise.. Annals of the New York Academy of Sciences, 1194, 130-5. https://doi.org/10.1111/j.1749-6632.2010.05482.x

MLA

Tuthill, Cynthia, et al. "Thymosin alpha 1: past clinical experience and future promise.." Annals of the New York Academy of Sciences, 2010. https://doi.org/10.1111/j.1749-6632.2010.05482.x

RethinkPeptides

RethinkPeptides Research Database. "Thymosin alpha 1: past clinical experience and future promis..." RPEP-01706. Retrieved from https://rethinkpeptides.com/research/tuthill-2010-thymosin-alpha-1-past

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.